Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease

19th March 2026 Uncategorised 0

Early trial shows more than 50% LRRK2 reduction and supports expansion into other neurodegenerative conditions

More: Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
Source: News